Display options
Cite
Rådestad E, Egevad L, Jorns C, et al. Characterization of infiltrating lymphocytes in human benign and malignant prostate tissue. Oncotarget. 2017;8(36):60257-60269doi: 10.18632/oncotarget.19528.
Rådestad, E., Egevad, L., Jorns, C., Mattsson, J., Sundberg, B., Nava, S., Ericzon, B. G., Henningsohn, L., Levitsky, V., & Uhlin, M. (2017). Characterization of infiltrating lymphocytes in human benign and malignant prostate tissue. Oncotarget, 8(36), 60257-60269. https://doi.org/10.18632/oncotarget.19528
Rådestad, Emelie, et al. "Characterization of infiltrating lymphocytes in human benign and malignant prostate tissue." Oncotarget vol. 8,36 (2017): 60257-60269. doi: https://doi.org/10.18632/oncotarget.19528
Rådestad E, Egevad L, Jorns C, Mattsson J, Sundberg B, Nava S, Ericzon BG, Henningsohn L, Levitsky V, Uhlin M. Characterization of infiltrating lymphocytes in human benign and malignant prostate tissue. Oncotarget. 2017 Jul 24;8(36):60257-60269. doi: 10.18632/oncotarget.19528. eCollection 2017 Sep 01. PMID: 28947968; PMCID: PMC5601136.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2017 Jul 24;8(36):60257-60269. doi: 10.18632/oncotarget.19528. eCollection 2017 Sep 01.

Characterization of infiltrating lymphocytes in human benign and malignant prostate tissue.

Oncotarget

Emelie Rådestad, Lars Egevad, Carl Jorns, Jonas Mattsson, Berit Sundberg, Silvia Nava, Bo-Göran Ericzon, Lars Henningsohn, Victor Levitsky, Michael Uhlin

Affiliations

  1. Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.
  2. Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
  3. Department of Pathology, Karolinska University Hospital, Stockholm, Sweden.
  4. Centre for Allogeneic Stem Cell Transplantation, Karolinska University Hospital, Stockholm, Sweden.
  5. Department of Urology, Karolinska University Hospital, Stockholm, Sweden.
  6. Molecular Partners AG, Schlieren-Zurich, Switzerland.
  7. Department of Immunology/Transfusion Medicine, Karolinska University Hospital, Stockholm, Sweden.
  8. Department of Applied Physics, Royal Institute of Technology, Stockholm, Sweden.

PMID: 28947968 PMCID: PMC5601136 DOI: 10.18632/oncotarget.19528

Abstract

Immune checkpoint blockade has shown promising results in numerous cancer types. However, in prostate cancer (PC), absent or limited responses have been reported. To investigate further, we compared the phenotype of infiltrating T-cells isolated from prostate tissue from patients with PC (

Keywords: PD-1; benign prostatic hyperplasia; checkpoint blockade; prostate cancer; prostate-infiltrating lymphocytes

Conflict of interest statement

CONFLICTS OF INTEREST The authors declare no potential conflicts of interest.

References

  1. Prostate. 2014 Oct;74(14):1391-9 - PubMed
  2. Blood. 2009 Aug 20;114(8):1537-44 - PubMed
  3. Oncotarget. 2016 Aug 16;7(33):52810-52817 - PubMed
  4. Eur J Cancer. 2009 Jun;45(9):1664-72 - PubMed
  5. Lab Invest. 2003 Aug;83(8):1131-46 - PubMed
  6. N Engl J Med. 2012 Jun 28;366(26):2443-54 - PubMed
  7. Cancer Immunol Res. 2015 Dec;3(12 ):1344-55 - PubMed
  8. Prostate. 2004 Jul 1;60(2):153-9 - PubMed
  9. Nat Immunol. 2009 Jan;10(1):29-37 - PubMed
  10. Inflamm Res. 2015 May;64(5):275-86 - PubMed
  11. Curr Opin Urol. 2006 Jan;16(1):25-9 - PubMed
  12. Cell. 2011 Mar 4;144(5):646-74 - PubMed
  13. J Immunol. 2009 Apr 1;182(7):4056-64 - PubMed
  14. Science. 2016 Dec 2;354(6316):1160-1165 - PubMed
  15. Eur Urol. 2007 May;51(5):1202-16 - PubMed
  16. J Exp Med. 2010 Sep 27;207 (10 ):2187-94 - PubMed
  17. Front Oncol. 2015 Jul 08;5:128 - PubMed
  18. J Clin Invest. 2015 Sep;125(9):3347-55 - PubMed
  19. Nat Rev Cancer. 2007 Apr;7(4):256-69 - PubMed
  20. Science. 2016 Dec 2;354(6316):1165-1169 - PubMed
  21. J Endocrinol. 2012 Jul;214(1):31-43 - PubMed
  22. Immunity. 2007 Oct;27(4):670-84 - PubMed
  23. J Clin Invest. 2014 May;124(5):2246-59 - PubMed
  24. PLoS One. 2016 May 06;11(5):e0154737 - PubMed
  25. J Immunol Res. 2016;2016:5601204 - PubMed
  26. Prostate. 2009 Nov 1;69(15):1694-703 - PubMed
  27. Biochem Pharmacol. 2015 Mar 15;94(2):53-62 - PubMed
  28. Lancet Oncol. 2014 Jun;15(7):700-12 - PubMed
  29. Histopathology. 2012 Jan;60(1):199-215 - PubMed
  30. Oncotarget. 2016 Apr 26;7(17):23581-93 - PubMed
  31. Rev Urol. 2002 Fall;4(4):171-7 - PubMed
  32. Nature. 2008 Jul 24;454(7203):436-44 - PubMed
  33. Immunity. 2011 Oct 28;35(4):467-77 - PubMed

Publication Types